Hussman Strategic Advisors Inc. Acquires Shares of 14,700 TransMedics Group, Inc. $TMDX

Hussman Strategic Advisors Inc. acquired a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 14,700 shares of the company’s stock, valued at approximately $1,788,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Two Sigma Investments LP raised its holdings in shares of TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after acquiring an additional 223,409 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of TransMedics Group by 11.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock valued at $119,997,000 after acquiring an additional 113,817 shares in the last quarter. Fred Alger Management LLC raised its holdings in shares of TransMedics Group by 303.8% during the third quarter. Fred Alger Management LLC now owns 150,741 shares of the company’s stock valued at $16,913,000 after acquiring an additional 113,408 shares in the last quarter. ArrowMark Colorado Holdings LLC raised its holdings in shares of TransMedics Group by 54.0% during the third quarter. ArrowMark Colorado Holdings LLC now owns 313,125 shares of the company’s stock valued at $35,133,000 after acquiring an additional 109,830 shares in the last quarter. Finally, Jump Financial LLC raised its holdings in shares of TransMedics Group by 482.7% during the third quarter. Jump Financial LLC now owns 127,032 shares of the company’s stock valued at $14,253,000 after acquiring an additional 105,232 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling

In related news, insider Anil P. Ranganath sold 864 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $139.12, for a total value of $120,199.68. Following the sale, the insider directly owned 13,091 shares of the company’s stock, valued at $1,821,219.92. This represents a 6.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Stephanie Lovell sold 1,193 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $149.62, for a total value of $178,496.66. Following the completion of the sale, the director directly owned 2,866 shares in the company, valued at approximately $428,810.92. The trade was a 29.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 16,205 shares of company stock valued at $2,353,002 over the last 90 days. 6.90% of the stock is currently owned by company insiders.

TransMedics Group Price Performance

Shares of TMDX stock opened at $100.01 on Friday. The stock has a market cap of $3.45 billion, a price-to-earnings ratio of 20.41 and a beta of 2.07. The business’s fifty day moving average is $117.36 and its 200 day moving average is $125.98. TransMedics Group, Inc. has a twelve month low of $89.10 and a twelve month high of $156.00. The company has a quick ratio of 6.59, a current ratio of 7.14 and a debt-to-equity ratio of 1.06.

Analyst Ratings Changes

A number of equities analysts recently commented on TMDX shares. TD Cowen restated a “buy” rating on shares of TransMedics Group in a report on Monday, March 16th. Oppenheimer upped their target price on TransMedics Group from $150.00 to $175.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Stifel Nicolaus upped their target price on TransMedics Group from $115.00 to $130.00 and gave the company a “hold” rating in a report on Monday, March 9th. Wall Street Zen downgraded TransMedics Group from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Finally, JPMorgan Chase & Co. upped their target price on TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $152.33.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.